Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Nonaspirin NSAIDs and contralateral breast cancer risk

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

Bens, A, Cronin-Fenton, D, Dehlendorff, C, Jensen, M-B, Ejlertsen, B, Kroman, N, Friis, S & Mellemkjaer, L 2019, 'Nonaspirin NSAIDs and contralateral breast cancer risk' International Journal of Cancer, bind 144, nr. 6, s. 1243-50. https://doi.org/10.1002/ijc.31949

APA

CBE

MLA

Vancouver

Author

Bens, Annet ; Cronin-Fenton, Deirdre ; Dehlendorff, Christian ; Jensen, Maj-Britt ; Ejlertsen, Bent ; Kroman, Niels ; Friis, Søren ; Mellemkjaer, Lene. / Nonaspirin NSAIDs and contralateral breast cancer risk. I: International Journal of Cancer. 2019 ; Bind 144, Nr. 6. s. 1243-50.

Bibtex

@article{c74f7b19092d4fbdbf702d13571da6ed,
title = "Nonaspirin NSAIDs and contralateral breast cancer risk",
abstract = "Laboratory studies suggest that inhibition of the cyclooxygenase (COX)-2 enzymes inhibits breast cancer development. We aimed to evaluate whether postdiagnosis use of COX-2 selective or other nonaspirin nonsteroidal anti-inflammatory drugs (NSAIDs) reduce the risk of contralateral breast cancer (CBC) among Danish breast cancer patients. From the clinical database of the Danish Breast Cancer Group, we identified 52,723 women diagnosed with breast cancer between 1996 and 2012. Data on nonaspirin NSAID use, CBC and potential confounding variables were obtained from nationwide registries. We defined postdiagnosis use (two or more prescriptions) as a time-varying covariate with a one-year lag. Cox proportional hazard regression models were used to estimate hazard ratios (HRs) and 95{\%} confidence intervals (CIs) for CBC associated with nonaspirin NSAID use. During a median follow-up of 4.8 years (interquartile range: 2.3-9 years), 1,444 patients were diagnosed with CBC. Overall, postdiagnosis use of nonaspirin NSAID was associated with an adjusted HR for CBC of 0.98 (95{\%} CI: 0.87-1.11). The HRs did not vary substantially with duration or intensity of nonaspirin NSAID use. Moreover, similar associations were found for COX-2 selective (HR: 1.02; 95{\%} CI: 0.85-1.23) and nonselective (HR: 0.96; 95{\%} CI: 0.82-1.13) nonaspirin NSAIDs. In conclusion, our nationwide cohort study of breast cancer patients does not suggest a reduced risk of CBC with nonaspirin NSAID use regardless of the COX-2 selectivity.",
author = "Annet Bens and Deirdre Cronin-Fenton and Christian Dehlendorff and Maj-Britt Jensen and Bent Ejlertsen and Niels Kroman and S{\o}ren Friis and Lene Mellemkjaer",
note = "{\circledC} 2018 UICC.",
year = "2019",
doi = "10.1002/ijc.31949",
language = "English",
volume = "144",
pages = "1243--50",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "JohnWiley & Sons, Inc",
number = "6",

}

RIS

TY - JOUR

T1 - Nonaspirin NSAIDs and contralateral breast cancer risk

AU - Bens, Annet

AU - Cronin-Fenton, Deirdre

AU - Dehlendorff, Christian

AU - Jensen, Maj-Britt

AU - Ejlertsen, Bent

AU - Kroman, Niels

AU - Friis, Søren

AU - Mellemkjaer, Lene

N1 - © 2018 UICC.

PY - 2019

Y1 - 2019

N2 - Laboratory studies suggest that inhibition of the cyclooxygenase (COX)-2 enzymes inhibits breast cancer development. We aimed to evaluate whether postdiagnosis use of COX-2 selective or other nonaspirin nonsteroidal anti-inflammatory drugs (NSAIDs) reduce the risk of contralateral breast cancer (CBC) among Danish breast cancer patients. From the clinical database of the Danish Breast Cancer Group, we identified 52,723 women diagnosed with breast cancer between 1996 and 2012. Data on nonaspirin NSAID use, CBC and potential confounding variables were obtained from nationwide registries. We defined postdiagnosis use (two or more prescriptions) as a time-varying covariate with a one-year lag. Cox proportional hazard regression models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for CBC associated with nonaspirin NSAID use. During a median follow-up of 4.8 years (interquartile range: 2.3-9 years), 1,444 patients were diagnosed with CBC. Overall, postdiagnosis use of nonaspirin NSAID was associated with an adjusted HR for CBC of 0.98 (95% CI: 0.87-1.11). The HRs did not vary substantially with duration or intensity of nonaspirin NSAID use. Moreover, similar associations were found for COX-2 selective (HR: 1.02; 95% CI: 0.85-1.23) and nonselective (HR: 0.96; 95% CI: 0.82-1.13) nonaspirin NSAIDs. In conclusion, our nationwide cohort study of breast cancer patients does not suggest a reduced risk of CBC with nonaspirin NSAID use regardless of the COX-2 selectivity.

AB - Laboratory studies suggest that inhibition of the cyclooxygenase (COX)-2 enzymes inhibits breast cancer development. We aimed to evaluate whether postdiagnosis use of COX-2 selective or other nonaspirin nonsteroidal anti-inflammatory drugs (NSAIDs) reduce the risk of contralateral breast cancer (CBC) among Danish breast cancer patients. From the clinical database of the Danish Breast Cancer Group, we identified 52,723 women diagnosed with breast cancer between 1996 and 2012. Data on nonaspirin NSAID use, CBC and potential confounding variables were obtained from nationwide registries. We defined postdiagnosis use (two or more prescriptions) as a time-varying covariate with a one-year lag. Cox proportional hazard regression models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for CBC associated with nonaspirin NSAID use. During a median follow-up of 4.8 years (interquartile range: 2.3-9 years), 1,444 patients were diagnosed with CBC. Overall, postdiagnosis use of nonaspirin NSAID was associated with an adjusted HR for CBC of 0.98 (95% CI: 0.87-1.11). The HRs did not vary substantially with duration or intensity of nonaspirin NSAID use. Moreover, similar associations were found for COX-2 selective (HR: 1.02; 95% CI: 0.85-1.23) and nonselective (HR: 0.96; 95% CI: 0.82-1.13) nonaspirin NSAIDs. In conclusion, our nationwide cohort study of breast cancer patients does not suggest a reduced risk of CBC with nonaspirin NSAID use regardless of the COX-2 selectivity.

U2 - 10.1002/ijc.31949

DO - 10.1002/ijc.31949

M3 - Journal article

VL - 144

SP - 1243

EP - 1250

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 6

ER -

ID: 55905463